Sharps Technology Inc. (NASDAQ: STSS)

Sharps Technology Inc. (STSS), a prominent player in the medical device industry, has made significant strides in the development and commercialization of safety syringes and innovative drug delivery systems. The company, which was initially incorporated in Wyoming in 2017 before reincorporating as a Nevada corporation in 2022, has its primary business address at 105 Maxess Road, Melville, New York 11747. Sharps Technology's common stock and warrants are publicly traded on the Nasdaq under the symbols STSS and STSSW, respectively.

Sharps Technology's primary business activities revolve around the design, production, and marketing of safety syringes. The company's product portfolio includes the Securegard, Sologard, and Sharps Provensa lines, all of which incorporate passive and active safety features. These syringes are designed to address the three primary concerns associated with syringe delivery systems: accidental needlestick injuries, wasted medicine, and reuse prevention. Sharps Technology's syringes stand out due to their ultra-low waste technology, which significantly reduces the amount of drug product discarded with each injection.

The medical device industry is highly competitive, with Sharps Technology facing stiff competition from domestic players such as Retractable Technologies, Inc., Becton Dickinson & Company, Medtronic Minimally Invasive Therapies, Terumo Medical Corp., Smiths Medical, and B Braun. However, Sharps Technology maintains a competitive edge due to its innovative products, which offer a safer and more efficient injection experience for healthcare workers and patients.

Sharps Technology's revenue generation is primarily driven by the sales of its safety syringe products. The Securegard, Sologard, and Sharps Provensa lines are the company's primary sources of income. These products cater to a wide range of customers, including hospitals, clinics, and other healthcare facilities. By providing a safer and more efficient injection experience, Sharps Technology's products have gained popularity among healthcare workers and patients alike.

The company's intellectual property rights, particularly its patent rights, are crucial to its business. Sharps Technology owns four patents related to the Sharps Provensa, which expire between 2035 and 2040. Additionally, the company has two pending patent applications in the United States and four PCT patent applications. These intellectual property rights not only protect the company's innovative products but also serve as a significant competitive advantage.

Sharps Technology's human capital comprises fifty-seven full-time employees, including its Chief Executive Officer and Chief Financial Officer. The company also retains the services of additional personnel on an independent contractor basis to support R&D, Finance, Marketing, and Regulatory areas. This diverse and skilled workforce is integral to the company's operations and success.